Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

NCT06164743 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Inflammation

Interventions

DRUG: VVN461 Ophthalmic Solution 1.0%
DRUG: VVN461 Ophthalmic Solution 0.5%
DRUG: Vehicle

Sponsor

VivaVision Biotech, Inc